Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.574 USD -1.37% Intraday chart for Traws Pharma, Inc. -7.52% -23.02%
May. 15 Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Traws Pharma : Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
North American Morning Briefing : Focus Turns to -2-
Traws Pharma, Inc. Announces Chief Executive Office Changes
Traws Pharma, Inc. Announces Board Changes
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics
Transcript : Onconova Therapeutics, Inc. - M&A Call
Traws Pharma Announces New Employee Inducement Grants
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. News Traws Pharma, Inc.
  5. Other languages